ACUT Accustem Sciences Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1850767 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.2%
TTM EPS YoY8.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-102.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets356.4%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-27.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $281,014 | $138,324 | $139,663 | $266,933 | $73,335 |
| SG&A expense | $1.48M | $1.37M | $1.91M | $3.48M | $597,279 |
| Operating income | -$1.76M | -$1.51M | -$2.05M | -$3.75M | -$670,614 |
| Pretax income | -$1.76M | -$1.51M | -$2.05M | -$3.75M | -$670,614 |
| Net income | -$1.76M | -$1.51M | -$2.05M | -$3.75M | -$670,614 |
| EBITDA | -$1.76M | -$1.50M | -$2.05M | -$3.74M | — |
| EPS (basic) | -0.12 | -0.13 | -0.18 | -0.34 | -0.07 |
| EPS (diluted) | -0.12 | -0.13 | -0.18 | -0.34 | — |
| Weighted avg. shares (diluted) | 15.23M | 11.44M | 11.35M | 11.02M | — |
| Balance sheet | |||||
| Cash & equivalents | $13,929 | $5,046 | $21,481 | $733,978 | — |
| Current assets | $49,446 | $50,433 | $129,849 | $932,011 | $1.35M |
| PP&E, net | — | $418 | $4,048 | $7,678 | — |
| Total assets | $1.55M | $50,851 | $133,897 | $939,689 | $1.35M |
| Current liabilities | $4.95M | $3.36M | $2.25M | $1.08M | $702,700 |
| Total liabilities | $4.95M | $3.36M | $2.25M | $1.08M | $702,700 |
| Shareholders' equity | -$3.40M | -$3.31M | -$2.11M | -$139,550 | $650,673 |
| Shares outstanding | 16.07M | 12.10M | 11.35M | 11.35M | 10.00M |
| Cash flow statement | |||||
| Operating cash flow | -$850,389 | -$664,066 | -$1.62M | -$1.81M | — |
| Capital expenditure | — | — | — | $10,999 | — |
| Free cash flow | — | — | — | -$1.82M | — |
| Investing cash flow | — | — | — | -$10,999 | — |
| Financing cash flow | $859,271 | $647,632 | $903,146 | $2.55M | — |
| Depreciation & amortization | $418 | $3,630 | $3,630 | $3,321 | — |
| Stock-based compensation | $88,695 | $69,718 | $78,634 | $133,889 | $21,260 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.